About biocryst pharmaceuticals inc. - BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
BCRX At a Glance
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham, North Carolina 27703-8457
| Phone | 1-919-859-1302 | Revenue | 874.84M | |
| Industry | Biotechnology | Net Income | 263.86M | |
| Sector | Health Technology | 2025 Sales Growth | 94.101% | |
| Fiscal Year-end | 12 / 2026 | Employees | 435 | |
| View SEC Filings |
BCRX Valuation
| P/E Current | 7.787 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 6.461 |
| Price to Sales Ratio | 1.949 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 5.17 |
| Enterprise Value to EBITDA | 5.571 |
| Enterprise Value to Sales | 2.18 |
| Total Debt to Enterprise Value | 0.25 |
BCRX Efficiency
| Revenue/Employee | 2,011,119.54 |
| Income Per Employee | 606,577.011 |
| Receivables Turnover | 8.19 |
| Total Asset Turnover | 1.742 |
BCRX Liquidity
| Current Ratio | 2.062 |
| Quick Ratio | 2.035 |
| Cash Ratio | 1.402 |
BCRX Profitability
| Gross Margin | 97.661 |
| Operating Margin | 38.977 |
| Pretax Margin | 30.565 |
| Net Margin | 30.161 |
| Return on Assets | 52.532 |
| Return on Equity | N/A |
| Return on Total Capital | 73.668 |
| Return on Invested Capital | 81.422 |
BCRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 133.267 |
| Total Debt to Total Assets | 92.837 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 122.075 |